The cobas SARS-CoV-2 and Influenza A/B Test for use on the cobas 6800/8800 Systems from Roche, Basel, Switzerland, has received FDA emergency use authorization. This test is intended for the simultaneous qualitative detection and differentiation of SARS-CoV-2, influenza A, and influenza B in patients suspected by their healthcare provider of having respiratory viral infection consistent with covid-19. The test is also available in markets accepting the CE mark. “With the approaching flu season, this new test is particularly important as SARS-CoV-2 and influenza infections can hardly be differentiated by symptoms alone. Now, with a single test, healthcare professionals can confidently provide the right diagnosis and most effective treatment plan for their patients,” says Thomas Schinecker, CEO of Roche Diagnostics. “As a leader in diagnostics testing solutions, this launch demonstrates our ongoing commitment to stop the spread of serious infectious diseases by increasing access to accurate, reliable and efficient testing options.” The SARS-CoV-2 and Influenza A/B Test runs on Roche’s fully-automated cobas 6800/8800 Systems, which provide up to 96 results in about 3 hours and 384 results for the cobas 6800 System and 1,056 results for the cobas 8800 System in an 8-hour shift. Roche is committed to delivering as many tests as possible within the limits of supply. For more information, visit Roche.
September 10, 2021
April 8, 2020